Miromatrix Medical Announces Closing of Initial Public Offering
Miromatrix Medical Inc. (Nasdaq: MIRO) announced the closing of its initial public offering (IPO) on June 28, 2021, selling 5,520,000 shares at $9.00 each, including an additional 720,000 shares purchased by underwriters.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (Nasdaq: MIRO) announced the closing of its initial public offering (IPO) on June 28, 2021, selling 5,520,000 shares at $9.00 each, including an additional 720,000 shares purchased by underwriters. The company raised approximately $49.7 million in gross proceeds, aimed at advancing its innovative technology for bioengineering transplantable human organs, focusing on livers and kidneys. This offering was facilitated by Craig-Hallum Capital Group as the managing underwriter.
Positive
- Raised approximately $49.7 million in gross proceeds to advance bioengineering technology.
- Focused on addressing the shortage of human organs with proprietary technology.
Negative
- Potential dilution of shares due to the IPO.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was +3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., June 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, today announced the closing of its initial public offering of 5,520,000 shares of common stock, including the full exercise by the underwriter of its option to purchase 720,000 shares at a price to the public of
Miromatrix received gross proceeds of approximately
Craig-Hallum Capital Group acted as sole managing underwriter for the offering.
A registration statement on Form S-1 relating to the shares being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on June 23, 2021. This offering was made only by means of a prospectus, copies of which may be obtained from: Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, by telephone at (612) 334-6300 or by email at prospectus@chlm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Miromatrix Medical
Miromatrix Medical Inc. (Nasdaq: MIRO), is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.